Intravitreal implants manufactured by supercritical foaming for treating retinal diseases
Journal of Controlled Release · 2023
DOI: 10.1016/j.jconrel.2023.08.047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Carlos Bendicho-Lavilla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Materials Institute iMATUS, University of Santiago de Co…. Hauptthemen laut MEDLINE: Dexamethasone, Drug Implants, Retinal Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chronic retinal diseases, such as age-related macular degeneration (AMD), are a major cause of global visual impairment. However, current treatment methods involving repetitive intravitreal injections pose financial and health burdens for patients. The development of controlled drug release systems, particularly for biological drugs, is still an unmet need in prolonging drug release within the vitreous chamber. To address this, green supercritical carbon dioxide (scCO2) foaming technology was employed to manufacture porous poly(lactic-co-glycolic acid) (PLGA)-based intravitreal implants loaded with dexamethasone. The desired implant dimensions were achieved through 3D printing of customised moulds. By varying the depressurisation rates during the foaming process, implants with different porosities and dexamethasone release rates were successfully obtained. These implants demonstrated controlled drug release for up to four months, surpassing the performance of previously developed implants. In view of the positive results obtained, a pilot study was conducted using the monoclonal antibody bevacizumab to explore the feasibility of this technology for preparing intraocular implants loaded with biologic drug molecules. Overall, this study presents a greener and more sustainable alternative to conventional implant manufacturing techniques, particularly suited for drugs that are susceptible to degradation under harsh conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Materials Institute iMATUS, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; Paraquasil Group…
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Materials Institute iMATUS and Health Research Institute of Santiago de Compostela (IDIS), Universidade de San…
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and Materials Institute iMATUS, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; Clinical Pharmaco…
Zitieren
APA
Bendicho-Lavilla, C., Seoane-Viaño, I., Santos-Rosales, V., Díaz-Tomé, V., Carracedo-Pérez, M., Luzardo-Álvarez, A. M., García-González, C. A., & Otero-Espinar, F. J. (2023). Intravitreal implants manufactured by supercritical foaming for treating retinal diseases. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.08.047
Vancouver
Bendicho-Lavilla C, Seoane-Viaño I, Santos-Rosales V, Díaz-Tomé V, Carracedo-Pérez M, Luzardo-Álvarez AM, et al. Intravitreal implants manufactured by supercritical foaming for treating retinal diseases. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.08.047
BibTeX
@article{BendichoLavilla2023,
author = {Bendicho-Lavilla, Carlos and Seoane-Viaño, Iria and Santos-Rosales, Víctor and Díaz-Tomé, Victoria and Carracedo-Pérez, María and Luzardo-Álvarez, Asteria M and García-González, Carlos A and Otero-Espinar, Francisco J},
title = {Intravitreal implants manufactured by supercritical foaming for treating retinal diseases},
journal = {Journal of Controlled Release},
year = {2023},
doi = {10.1016/j.jconrel.2023.08.047}
}
EUVIMED